Development of a scaleable, sustainable manufacutring process for a novel, high-value polypeptide

Leukolectin是一种新型的专利分子，在临床前试验中表现出对治疗一系列皮肤，自身免疫和胃肠道疾病的显着益处。Leukolectin在许多疾病状态中不存在，这表明它的存在对于预防所列疾病至关重要。通过开发一系列含有Leukolectin的局部和口服药物，Seagarden是一家生产海鲜成分和海洋生物活性物质的挪威公司，希望能显著改善世界各地数百万患者所经历的症状的严重程度。该项目将由英国酶开发商和制造商Biocatalysts Ltd推动，该公司在大规模生产白细胞凝集素等蛋白质方面拥有丰富的经验。通过发酵生产白细胞凝集素将确保这些医疗营养产品的生产成本保持在最低水平，并且使用可持续和环境友好的工艺生产白细胞凝集素。

Leukolectin is a novel, patented molecule, exhibiting (in pre-clinical tests) remarkable benefits for the treatment of a range of skin, autoimmune and gastrointestinal disorders. Leukolectin is absent in many disease states, suggesting that its presence is critical for preventing the listed ailments. By creating a range of topical and oral medicaments containing Leukolectin, Seagarden, a Norwegian company who manufacture seafood ingredients and marine bioactives, hope to dramatically improve the severity of symptoms experienced by millions of suffers around the World. The project will be facilitated by Biocatalysts Ltd, a UK enzyme developer and manufacturer, who have vast experience of large-scale manufacturing of proteins such as leukolectin. Production of leukolectin via fermentation will ensure that production costs of these medical nutrition products are kept to a minimum, and that leukolectin is produced using a sustainable and environmentally-friendly process.